Endoscopic sleeve gastroplasty versus oral semaglutide for obesity: a real-world comparative cohort study.

Jagtap N, Golchha A, Katrevula A, Asif S, Rughwani H, Koduri KK, Balenki P, Kalapala R, Reddy DN

Endoscopy8 Jun 2026

PMID42259388DOI10.1055/a-2891-4165PepBankPUB-42259388

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In adults with obesity, oral semaglutide 14 mg gave a mean total body weight loss of 8.67% at 6 months, significantly less than ESG (12.72%).
In plain wordsIn adults with obesity, oral semaglutide led to a mean 8.67% weight loss at 6 months, less than with the endoscopic procedure.
Peptide
Semaglutide
Outcome
DecreasePercentage total body weight loss at 6 months
Study
n = 150
Comparator
Endoscopic sleeve gastroplasty
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
14 mg daily · oral · 6 monthsAs given in this study (human).
Measurements
%TBWL
8.67%
oral semaglutide, 6 months
Source sentences
Summary
At 6 months, mean %TBWL was significantly higher with ESG than semaglutide (12.72±5.67% vs 8.67±3.84%, P=0.0001) that remained after covariate adjustment (adjusted mean difference 4.04%, P=0.0001), IPTW analysis (PP=0.021).
1 context sentence(design, population, supporting numbers)
Summary · context
In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18-65 years with body mass index (BMI) ≥30, or ≥27 kg/m² with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months' follow-up were included.
Report a problemFND-4225938801
02HumanObservational studyEfficacy outcome
In adults with obesity, 43% of patients on oral semaglutide reached at least 10% total body weight loss versus 70% with ESG.
In plain wordsIn adults with obesity, 43% of people on oral semaglutide lost at least 10% of body weight, compared with 70% after the endoscopic procedure.
Peptide
Semaglutide
Outcome
DecreaseResponder rate, at least 10% total body weight loss
Study
n = 150
Comparator
Endoscopic sleeve gastroplasty
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
14 mg daily · oral · 6 monthsAs given in this study (human).
Measurements
Responders >=10% TBWL
43%
oral semaglutide
Source sentences
Summary
Responder rates ≥10%TBWL were achieved in 70% with ESG versus 43% with semaglutide (relative risk [RR] 0.62, 95%CI 0.46-0.82, P=0.0009)
1 context sentence(design, population, supporting numbers)
Summary · context
In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18-65 years with body mass index (BMI) ≥30, or ≥27 kg/m² with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months' follow-up were included.
Report a problemFND-4225938802
03HumanObservational studyEfficacy outcome
In adults with obesity, 7% of patients on oral semaglutide reached at least 15% total body weight loss versus 36% with ESG.
In plain wordsIn adults with obesity, 7% of people on oral semaglutide lost at least 15% of body weight, compared with 36% after the endoscopic procedure.
Peptide
Semaglutide
Outcome
DecreaseResponder rate, at least 15% total body weight loss
Study
n = 150
Comparator
Endoscopic sleeve gastroplasty
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
14 mg daily · oral · 6 monthsAs given in this study (human).
Measurements
Responders >=15% TBWL
7%
oral semaglutide
Source sentences
Summary
and ≥15%TBWL in 36% versus 7% (RR 0.20, 95%CI 0.09-0.44, P=0.0006).
1 context sentence(design, population, supporting numbers)
Summary · context
In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18-65 years with body mass index (BMI) ≥30, or ≥27 kg/m² with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months' follow-up were included.
Report a problemFND-4225938803
04HumanObservational studySafety outcome
In adults with obesity treated with ESG or oral semaglutide 14 mg, there were no major adverse events.
In plain wordsIn adults with obesity, no major side effects were reported with either oral semaglutide or the endoscopic procedure.
Peptide
Semaglutide
Outcome
No significant changeMajor adverse events
Study
n = 150
Comparator
Endoscopic sleeve gastroplasty
Analysis
Secondary
Outcome group
Adverse events · Whole body
Studied dose
14 mg daily · oralAs given in this study (human).
Source sentences
Summary
There were no major adverse events.
1 context sentence(design, population, supporting numbers)
Summary · context
In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18-65 years with body mass index (BMI) ≥30, or ≥27 kg/m² with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months' follow-up were included.
Report a problemFND-4225938805
05HumanObservational studyEfficacy outcome
In adults with obesity, oral semaglutide gave a mean total body weight loss of 10.91% at 12 months, with no significant difference from ESG (11.92%).
In plain wordsIn adults with obesity, weight loss on oral semaglutide at 12 months (10.91%) was not significantly different from the endoscopic procedure.
Peptide
Semaglutide
Outcome
No significant changePercentage total body weight loss at 12 months
Study
n: not reported in source
Comparator
Endoscopic sleeve gastroplasty
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
14 mg daily · oral · 12 monthsAs given in this study (human).
Measurements
%TBWL
10.91%
oral semaglutide, 12 months
Source sentences
Summary
At 12 months, mean %TBWL was 11.92±6.93 with ESG and 10.91±4.66 with semaglutide (P=0.41).
1 context sentence(design, population, supporting numbers)
Summary · context
In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18-65 years with body mass index (BMI) ≥30, or ≥27 kg/m² with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months' follow-up were included.
Report a problemFND-4225938804
06HumanObservational studySafety outcome
In adults with obesity, 18 patients discontinued oral semaglutide during follow-up.
In plain wordsIn adults with obesity, 18 people stopped taking oral semaglutide during follow-up.
Peptide
Semaglutide
Outcome
Not applicableDiscontinuation of semaglutide
Study
n = 100
Comparator
Endoscopic sleeve gastroplasty
Outcome group
Adverse events · Whole body
Studied dose
14 mg daily · oralAs given in this study (human).
Source sentences
Summary
During follow-up, 18 patients discontinued semaglutide
1 context sentence(design, population, supporting numbers)
Summary · context
In a real-world retrospective comparative cohort study between January 2024 and April 2025, adults aged 18-65 years with body mass index (BMI) ≥30, or ≥27 kg/m² with obesity-related comorbidity, treated with either ESG or oral semaglutide 14mg daily, and having 6-months' follow-up were included.
Report a problemFND-4225938806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.